DK1002108T3 - Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling - Google Patents

Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling

Info

Publication number
DK1002108T3
DK1002108T3 DK98945090T DK98945090T DK1002108T3 DK 1002108 T3 DK1002108 T3 DK 1002108T3 DK 98945090 T DK98945090 T DK 98945090T DK 98945090 T DK98945090 T DK 98945090T DK 1002108 T3 DK1002108 T3 DK 1002108T3
Authority
DK
Denmark
Prior art keywords
mhc class
lag
adjuvant
vaccination
ligands
Prior art date
Application number
DK98945090T
Other languages
Danish (da)
English (en)
Inventor
Frederique Triebel
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of DK1002108T3 publication Critical patent/DK1002108T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98945090T 1997-07-25 1998-07-23 Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling DK1002108T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (fr) 1997-07-25 1997-07-25 Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer

Publications (1)

Publication Number Publication Date
DK1002108T3 true DK1002108T3 (da) 2006-08-21

Family

ID=8229825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98945090T DK1002108T3 (da) 1997-07-25 1998-07-23 Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling

Country Status (19)

Country Link
US (2) US6410509B1 (fr)
EP (3) EP0893507A1 (fr)
JP (1) JP4723722B2 (fr)
KR (1) KR100603075B1 (fr)
CN (1) CN1184320C (fr)
AT (2) ATE324455T1 (fr)
AU (1) AU753738B2 (fr)
BR (1) BR9811037A (fr)
CA (2) CA2293805C (fr)
DE (2) DE69841866D1 (fr)
DK (1) DK1002108T3 (fr)
EA (3) EA200300092A1 (fr)
EE (1) EE200000039A (fr)
ES (1) ES2262242T3 (fr)
IL (2) IL134212A0 (fr)
NO (1) NO20000378D0 (fr)
PT (1) PT1002108E (fr)
UA (1) UA75322C2 (fr)
WO (1) WO1999004810A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519779T1 (de) * 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (fr) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode
EP2044949A1 (fr) * 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
WO2011031139A1 (fr) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. Protéine ataq ou fragment de celle-ci pouvant être utilisé en tant que vaccin
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9187751B2 (en) 2010-11-10 2015-11-17 Laboratorios Leti, S.L. Adjuvant
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
WO2016056596A1 (fr) 2014-10-07 2016-04-14 日本電気株式会社 Peptide dérivé de hsp70, et procédé de fabrication de composition pharmaceutique, inducteur d'immunité, et cellule présentatrice d'antigène permettant le traitement ou la prévention du cancer l'utilisant
WO2016094639A1 (fr) * 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Vaccins d'adn de plasmide mini-introniques en combinaison avec un blocage lag3
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US10526388B2 (en) 2015-03-09 2020-01-07 Cytlimic Inc. Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
AU2016244570B2 (en) * 2015-04-07 2020-08-27 Nec Corporation Medicine
EP3294324A1 (fr) 2015-05-13 2018-03-21 Agenus Inc. Vaccins pour le traitement et la prévention du cancer
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017046409A1 (fr) 2015-09-18 2017-03-23 Rijksuniversiteit Groningen Inuline à longue chaîne pour stimuler une réponse immunitaire
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
EP3784688A2 (fr) 2018-04-26 2021-03-03 Agenus Inc. Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
CN113271970A (zh) * 2018-09-27 2021-08-17 健诺西生物科学公司 治疗方法
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
WO1990001870A1 (fr) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Vecteurs de retrovirus exprimant des cd4 solubles: therapie genique pour le sida
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
EP0385909B1 (fr) * 1989-03-03 1994-07-13 MicroGeneSys, Inc. Kit ou composition pour la prévention ou le traitement des infections par HIV-1
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
ES2249760T3 (es) * 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
JP3700859B2 (ja) * 1994-05-06 2005-09-28 アンスティテュ ギュスタブ ルシ Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体
MX9700560A (es) * 1994-08-05 1997-05-31 Warner Lambert Co Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
CZ172497A3 (en) * 1994-12-07 1997-10-15 Hoffmann La Roche Fragments of monoclonal substance exhibiting immunosuppressor activity
CN1171117A (zh) * 1994-12-23 1998-01-21 实验室奥姆公司 Mhc－ⅱ结合和/或mhc－ⅱ模拟分子用于预防和/或治疗炎性疾病的用途
ES2191784T3 (es) * 1995-12-28 2003-09-16 Univ Johns Hopkins Med Vacunas de tumores de citocinas paracrinas alogenicas.

Also Published As

Publication number Publication date
EA005405B1 (ru) 2005-02-24
ATE324455T1 (de) 2006-05-15
CA2293805C (fr) 2011-05-03
CN1265149A (zh) 2000-08-30
EE200000039A (et) 2000-10-16
AU753738B2 (en) 2002-10-24
UA75322C2 (en) 2006-04-17
DE69841866D1 (de) 2010-10-07
EP1002108B1 (fr) 2006-04-26
NO20000378L (no) 2000-01-25
US7109026B2 (en) 2006-09-19
IL134212A (en) 2012-03-29
JP2001510806A (ja) 2001-08-07
CA2732570A1 (fr) 1999-02-04
KR100603075B1 (ko) 2006-07-20
EA003740B1 (ru) 2003-08-28
US6410509B1 (en) 2002-06-25
ATE478956T1 (de) 2010-09-15
BR9811037A (pt) 2000-08-01
HK1030014A1 (en) 2001-04-20
CN1184320C (zh) 2005-01-12
CA2293805A1 (fr) 1999-02-04
KR20010021706A (ko) 2001-03-15
US20020192195A1 (en) 2002-12-19
NO20000378D0 (no) 2000-01-25
EP1002108A2 (fr) 2000-05-24
DE69834330D1 (de) 2006-06-01
DE69834330T2 (de) 2007-03-29
EP1698701A1 (fr) 2006-09-06
WO1999004810A2 (fr) 1999-02-04
CA2732570C (fr) 2014-11-18
WO1999004810A3 (fr) 1999-07-08
JP4723722B2 (ja) 2011-07-13
EP1698701B1 (fr) 2010-08-25
PT1002108E (pt) 2006-09-29
AU9254798A (en) 1999-02-16
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (fr) 1999-01-27
IL134212A0 (en) 2001-04-30
EA200200565A1 (ru) 2002-10-31
EA200300092A1 (ru) 2003-06-26
ES2262242T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20000378D0 (no) Anvendelse av MHC klasse II ligander som adjuvantia for vaksinasjon og LAG-3 i kreftbehandling
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR8300475A (pt) Composto, composicao farmaceutica, processo para tratamento de infeccao virotica em um animal de sangue quente ou de sangue frio, e processo para a preparacao de tal composto
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
DK16487A (da) Vacciner til oral indgift
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
EP0722324A4 (fr) Composition pharmaceutique s'utilisant pour une therapie de renforcement immunitaire
CA2034484A1 (fr) Radio-immunotherapie faisant appel a des emissions de particules-d
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE60015084D1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
DK0983072T3 (da) Fruktanholdige sammensætninger til forebyggelse og behandling af coloncancer
DE68921150D1 (de) Wirkung von hormonen.
EP1037918A4 (fr) Procede et composition pour ameliorer l'efficacite d'un vaccin
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
WO2000055194A3 (fr) Antigenes de la tuberculose et procedes de leur utilisation
WO1998035045A3 (fr) Antigenes leishmania utilises dans le traitement et le diagnostic de la leishmaniose
WO2002072013A3 (fr) Methode de traitement de malignites par l'induction de reponses immunitaires dans le sang
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
DK0835309T3 (da) Vaccine imod infektiøse agenser, præparat til behandling og forebyggelse af HIV infektioner
MD950010A (ro) Compoziţie pentru înlăturarea sau dezactivarea componentelor dăunătoare în sînge sau alte lichide extracelulare ale organismului şi procedeu de obţinere